Literature DB >> 3481324

Penetration of ofloxacin from blood to sputum.

B I Davies1, F P Maesen, W H Geraedts, C Baur.   

Abstract

Serum and sputum concentrations of ofloxacin were measured by a microbiological agar-well diffusion assay in nearly 100 patients after single 400, 600 or 800 mg doses of ofloxacin. All patients were admitted to hospital because of acute purulent exacerbations of chronic respiratory disease, and the concentration studies were performed on the first treatment day while the sputum was still purulent. Both blood and sputum samples were tested at standardised time intervals after dosage, and concentration-time curves were constructed. Cmax values in serum and sputum were 3.7 and 2.7 mg/L after 400 mg ofloxacin, 7.1 and 6.1 mg/L after 600 mg and 8.8 and 6.3 mg/L after 800 mg. Penetration from blood to sputum, as judged from ratio of AUC values for sputum and serum, varied from 78 to 103%.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3481324     DOI: 10.2165/00003495-198700341-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  6 in total

1.  A simple computer program for calculating areas under concentration-time curves.

Authors:  B E Storey; B I Davies
Journal:  J Antimicrob Chemother       Date:  1986-08       Impact factor: 5.790

2.  Cefoperazone in acute exacerbations of chronic bronchitis.

Authors:  B I Davies; F P Maesen; J Brouwers
Journal:  J Antimicrob Chemother       Date:  1982-02       Impact factor: 5.790

3.  The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.

Authors:  P D Ellner; H C Neu
Journal:  JAMA       Date:  1981-10-02       Impact factor: 56.272

4.  Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study.

Authors:  B I Davies; F P Maesen; J P Teengs
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

5.  Pefloxacin in acute exacerbations of chronic bronchitis.

Authors:  F P Maesen; B I Davies; J P Teengs
Journal:  J Antimicrob Chemother       Date:  1985-09       Impact factor: 5.790

6.  Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis.

Authors:  B I Davies; F P Maesen; C Baur
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

  6 in total
  5 in total

Review 1.  Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

2.  Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever.

Authors:  D B Bethell; N P Day; N M Dung; C McMullin; H T Loan; D T Tam; L T Minh; N T Linh; N Q Dung; H Vinh; A P MacGowan; L O White; N J White
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 3.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

4.  Intraoperative concentrations of ofloxacin in serum, bile fluid, and gallbladder wall tissue.

Authors:  A Chin; M P Okamoto; M A Gill; D A Sclar; T V Berne; A E Yellin; P N Heseltine; M D Appleman
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 5.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.